Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
16,121 stopped studies · 89% state a reason
Over the 16,121 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT03695250 | BMS-986205 and Nivolumab as First or Second Line Therapy in Treating Patients With Liver… | Phase 1 / Phase 2 | terminated | Oct 4, 2018 | Edward Kim | Funding source decision to terminate study. | Funding |
| NCT04797702 | Glumetinib Combined With Toripalimab in the Treatment of Relapsed or Metastatic Non-small…(CT32) | Phase 1 / Phase 2 | terminated | Mar 15, 2021 | Shanghai Junshi Bioscience Co., Ltd. | The company's research strategy was adjusted and the study was terminated | Sponsor / business decision |
| NCT04974944 | First-line Treatment With Camrelizumab + Apatinib Versus Chemotherapy + Bevacizumab in… | Phase 2 | terminated | Jul 23, 2021 | Sun Yat-Sen University Cancer Center | No superior PFS in study group among the enrolled patients. Company R\&D strategy shifted; funding… | Enrollment / accrual |
| NCT05081180 | Study of Avelumab in Combination With Lenvatinib for Children With Primary CNS Tumors | Phase 1 | terminated | Oct 18, 2021 | EMD Serono Research & Development Institute, Inc. | The study was stopped due to a lack of clear evidence of anti-tumor activity with the combination… | Other (stated, no rule matched) |
| NCT05322577 | A Study Evaluating Bemarituzumab in Combination With Other Anti-cancer Therapies in…(FORTITUDE-103) | Phase 1 / Phase 2 | terminated | Apr 12, 2022 | Amgen | Sponsor Decision | Sponsor / business decision |
| NCT05926362 | Capillary-Venous Paired Data Collection(CaVeP-DC) | — | suspended | Jul 3, 2023 | Entia Ltd | Paused for interim analysis | Efficacy / futility |
| NCT06183151 | Capillary-Venous Paired Collection(CaVe) | — | suspended | Dec 27, 2023 | Entia Ltd | Recruitment Paused for data review | Enrollment / accrual |
| NCT06622226 | A Study of ONO-7018 in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma | Phase 1 | terminated | Oct 2, 2024 | Ono Pharmaceutical Co., Ltd. | Sponsor decided to discontinue development of the compound | Sponsor / business decision |
| NCT03598608 | Study to Evaluate the Safety and Efficacy of a Combination of Favezelimab (MK-4280) and… | Phase 1 / Phase 2 | terminated | Jul 26, 2018 | Merck Sharp & Dohme LLC | Business Reason | Sponsor / business decision |
| NCT03744715 | A Study to Allow Continued Dosing and/or Follow-up of Patients Who Have Had Previous… | Phase 2 | terminated | Nov 16, 2018 | Spectrum Pharmaceuticals, Inc | Business reasons, not related to safety. | Safety / toxicity |
| NCT01876771 | A Trial to Assess the Safety and Effectiveness of Lutetium-177 Octreotate Therapy in… | Phase 2 | suspended | Jun 13, 2013 | AHS Cancer Control Alberta | Study closed to accrual given widespread availability of the similar marketed product,… | Enrollment / accrual |
| NCT03178123 | The Study of JS001 Compared to High-Dose Interferon In Patients With Mucosal Melanoma… | Phase 2 | terminated | Jun 6, 2017 | Shanghai Junshi Bioscience Co., Ltd. | The study strategy was adjusted, and the company decided to terminate the study early | Sponsor / business decision |
| NCT03203525 | Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating… | Phase 1 | terminated | Jun 29, 2017 | M.D. Anderson Cancer Center | \<75% participation | Other (stated, no rule matched) |
| NCT03417739 | A Phase II Study of BVD-523 in Metastatic Uveal Melanoma | Phase 2 | terminated | Jan 31, 2018 | Dana-Farber Cancer Institute | This was a Simon two stage design trial that terminated after the first stage due to lack of… | Other (stated, no rule matched) |
| NCT04364672 | Molecular Neuroimaging to Assess the Link Between Neuroinflammation and Cognitive… | Phase 1 | withdrawn | Apr 28, 2020 | University of Alabama at Birmingham | lack of recruitment and funding | Enrollment / accrual |
| NCT05616624 | ADI-PEG 20 in Combination With Gemcitabine and Docetaxel After Progression on Frontline… | Phase 1 / Phase 2 | terminated | Nov 15, 2022 | Washington University School of Medicine | Polaris has decided to close to accrual due to low enrollment | Enrollment / accrual |
| NCT05754749 | Comparison of CE-DBT and MRI in Patients With Known Breast Lesions | Early Phase 1 | terminated | Mar 6, 2023 | UNC Lineberger Comprehensive Cancer Center | Funding unavailable | Funding |
| NCT07242690 | PET-CT Imaging With PCD-CT | N/A | suspended | Nov 21, 2025 | Medical University of South Carolina | Study team is working on contracts. | Other (stated, no rule matched) |
| NCT05408520 | Targeted Muscle Reinnervation Study (TMR)(TMR) | N/A | withdrawn | Jun 7, 2022 | University of Arizona | Study not conducted | Other (stated, no rule matched) |
| NCT05826600 | A Study of OMX-0407 in Patients With Previously Treated Solid Tumours That Can't be… | Phase 1 / Phase 2 | terminated | Apr 24, 2023 | iOmx Therapeutics AG | Study terminated as part of strategic considerations and not based on safety concerns. | Safety / toxicity |
| NCT06929260 | A Study to Evaluate the Effect of Ceralasertib on Drug X, Drug Y and Drug Z | Phase 1 | terminated | Apr 16, 2025 | AstraZeneca | The study terminated because the clinical development programme for Ceralasertib has been… | Other (stated, no rule matched) |
| NCT03835273 | Oesophagectomy and Chest Wall and Respiratory Function | — | terminated | Feb 8, 2019 | Imperial College London | Study closed before the planned recruitment target was reached because the study period ended… | Enrollment / accrual |
| NCT03941366 | Treatment of Adenocarcinoma of the Rectum With Transanal Local Excision for Complete… | N/A | terminated | May 7, 2019 | Henry Ford Health System | Lack of financial support | Funding |
| NCT05180474 | GEN1047 for Solid Tumors - First in Human (FIH) Trial | Phase 1 / Phase 2 | terminated | Jan 6, 2022 | Genmab | The Sponsor has made a strategic decision to stop the development of GEN1047. | Sponsor / business decision |
| NCT05526079 | Watchful Waiting for Complete Responders to Therapy in Rectal Cancer | N/A | terminated | Sep 2, 2022 | Henry Ford Health System | Lack of financial support | Funding |
| NCT05714553 | NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours | Phase 1 / Phase 2 | terminated | Feb 6, 2023 | NuCana plc | The NuTide:303 study was terminated at NuCana's discretion following refinement of the NUC-3373… | Sponsor / business decision |
| NCT06008483 | A Dose Finding Study to Treat Bone Tumor(s) | Phase 1 | terminated | Aug 23, 2023 | QSAM Therapeutics, Inc. | Change in development program indication | Other (stated, no rule matched) |
| NCT06022757 | Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With… | Phase 1 / Phase 2 | terminated | Sep 5, 2023 | Evopoint Biosciences Inc. | Strategic decision by Sponsor. | Sponsor / business decision |
| NCT06509919 | Application of a Novel Model Based on Plasma cfDNA Assay and MRl Imaging in the Detection… | — | suspended | Jul 19, 2024 | Shanghai Changzheng Hospital | Modifications to trial design | Other (stated, no rule matched) |
| NCT06586658 | Anti-CD70-CAR-T Cell Injection for the Treatment of Locally Advanced or… | Early Phase 1 | suspended | Sep 19, 2024 | Shanghai Changzheng Hospital | Modifications to the trial design | Other (stated, no rule matched) |
| NCT00788307 | Gene Therapy and Radioactive Iodine in Treating Patients With Locally Recurrent Prostate… | Phase 1 | terminated | Nov 10, 2008 | Mayo Clinic | closed early due to poor accrual | Enrollment / accrual |
| NCT02546986 | Safety and Efficacy Study of CC-486 With MK-3475 to Treat Locally Advanced or Metastatic… | Phase 2 | terminated | Sep 11, 2015 | Celgene | not stated | Not stated |
| NCT03065387 | Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With… | Phase 1 | terminated | Feb 27, 2017 | M.D. Anderson Cancer Center | \<75% participation | Other (stated, no rule matched) |
| NCT03786081 | Safety and Efficacy of Tisotumab Vedotin Monotherapy & in Combination With Other Cancer… | Phase 1 / Phase 2 | terminated | Dec 24, 2018 | Seagen, a wholly owned subsidiary of Pfizer | Sponsor has decided to stop the trial based on strategic decisions | Sponsor / business decision |
| NCT04163432 | Staggered, Chemo-Immunotherapy With Durvalumab, MEDI4736 Pemetrexed & Carboplatin (PC)…(STAGGER) | Phase 2 | terminated | Nov 14, 2019 | University of Utah | Closed due to slow accrual | Enrollment / accrual |
| NCT04419909 | Retreatment With CTL019/CTL119 | Phase 1 | withdrawn | Jun 9, 2020 | University of Pennsylvania | Lack of Eligible Subjects | Other (stated, no rule matched) |
| NCT04461509 | High Resolution, 18F-PSMA PET-MRI Before Prostate Cancer HIFU or Radical Prostatectomy | Phase 2 | terminated | Jul 8, 2020 | Alessandro D'Agnolo | Funding ceased before all specimen collection and analysis could be completed | Funding |
| NCT05689021 | CJNJ-67652000 and Prednisone for Treatment of Metastatic Castration-Resistant Prostate… | Phase 2 | terminated | Jan 18, 2023 | Mayo Clinic | Sponsor decided to close due to slow accrual and lack of efficacy | Efficacy / futility |
| NCT06665776 | HLA-A*02:01 Allele Frequency and the NY-ESO-1 Expression Status in Cancer Patients in… | — | terminated | Oct 30, 2024 | PharmaEssentia | Because the Phase I trial will not go forward, patient recruitment for the pre-screening study has… | Enrollment / accrual |
| NCT06666218 | Helping Ovarian Cancer Patients Cope With Their Illness (HOPE) | N/A | suspended | Oct 30, 2024 | Fred Hutchinson Cancer Center | Enrollment is currently paused. Aim 1 recruitment has finished, and the study team is preparing to… | Enrollment / accrual |
| NCT06691685 | A Clinical Study to Evaluate the Safety and Efficacy of ESO-T01 in Treating… | Early Phase 1 | suspended | Nov 15, 2024 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | The collaborator EsoBiotec was acquired by AstraZeneca. | Other (stated, no rule matched) |
| NCT03445000 | ALEctinib for the Treatment of Pretreated RET-rearranged Advanced Non-small Cell Lung…(ALERT-lung) | Phase 2 | terminated | Feb 26, 2018 | ETOP IBCSG Partners Foundation | Low recruitment rate | Enrollment / accrual |
| NCT04155190 | A Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently… | Phase 2 | terminated | Nov 7, 2019 | Sol-Gel Technologies, Ltd. | Terminated early due to low blinded event rate | Other (stated, no rule matched) |
| NCT05026736 | Sintilimab for the Treatment of Locally Advanced, Metastatic, or Recurrent Angiosarcoma,… | Phase 2 | terminated | Aug 30, 2021 | M.D. Anderson Cancer Center | PI request, \<75% participation | Other (stated, no rule matched) |
| NCT05377827 | Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of… | Phase 1 | suspended | May 17, 2022 | Washington University School of Medicine | Drugs/Equipment Unavailable | Other (stated, no rule matched) |
| NCT05618613 | Study of Elacestrant in Combination With Onapristone in Patients With Advanced or…(ELONA) | Phase 1 / Phase 2 | terminated | Nov 16, 2022 | Context Therapeutics Inc. | Sponsor decision to discontinue onapristone development. | Sponsor / business decision |
| NCT05660395 | A Study to Evaluate the Pharmacokinetics and Safety of Loncastuximab Tesirine in… | Phase 1 | terminated | Dec 21, 2022 | ADC Therapeutics S.A. | This decision to close the study was made following interactions with regulatory authorities and in… | Safety / toxicity |
| NCT05823467 | What is Optimal Post-operative Prophylactic Therapy in Irradiated Breasts Undergoing… | N/A | terminated | Apr 21, 2023 | University of Alberta | Logistical Issues | Other (stated, no rule matched) |
| NCT06226129 | Gadopiclenol in Contrast Enhanced MRI of the Prostate | Phase 4 | suspended | Jan 26, 2024 | Columbia University | The study is being transferred to another institution | Other (stated, no rule matched) |
| NCT00707473 | Docetaxel, Cisplatin and Fluorouracil in Treating Patients With Previously Untreated… | Phase 2 | terminated | Jun 30, 2008 | M.D. Anderson Cancer Center | \<75% participation | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Jul 29, 2026source: clinicaltrials